Author

Abhishek A. Chakraborty

Cleveland ClinicORCID 0000-0002-3382-188XUnclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Abhishek A. Chakraborty1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Assay:structural biology· 1

Frequent Co-Authors

Alexander EarsleyiD· 1 shared Ananthan SadagopaniD· 1 shared Autumn Hall· 1 shared Belinda B. WillardiD· 1 shared Biao QiuiD· 1 shared Carleigh Salem· 1 shared Christopher M. GoinsiD· 1 shared Dehui Mi· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander EarsleyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Death and DiseasePeer-reviewedSep 11, 2026

BCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers

Tupa Basuroy, Treg M. Grubb, Ananthan Sadagopan…·Abhishek A. Chakraborty

The paper identifies BCL-XL dependence as a common vulnerability in various kidney cancer subtypes and develops a model to predict it using biomarkers like AMPK activation.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 3, 2025

Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer

Pooneh Koochaki, Biao Qiu, Jesse A. Coker…·Abhishek A. Chakraborty

This study determines the cryo-EM structure of SLC1A1 bound to an inhibitor, identifies its binding mechanism, and develops improved inhibitors with enhanced cytotoxicity in kidney cancer cells.

DOI 10.1101/2025.07.03.663021

humanstructural biology

𝕏 PostBluesky